MA-ICP-GROUP
4.1.2021 22:07:16 CET | Business Wire | Press release
Innovative Chemical Products (“ICP Group” or “ICP”), a leader in specialty coatings, adhesives and building envelope solutions, announced today that it has acquired Gardner-Gibson and Sun Coatings (“Gardner-Gibson”), a leading manufacturer of liquid-applied roof coatings, roofing products, driveway sealers and specialty paints primarily serving professional contractors for commercial and residential applications. The acquisition builds upon ICP Group’s extensive line of building solutions and global distribution network and creates one of the largest privately held coatings and adhesives companies in North America.
“The Gardner-Gibson acquisition and combination with ICP Group will strengthen the product offerings and distribution network for both companies,” said Doug Mattscheck, CEO, ICP Group. “We were strong individually and will be even stronger together as we enhance our portfolio of coatings, adhesives and building envelope solutions. ICP Group welcomes the Gardner-Gibson employees to the ICP family and looks forward to supporting the continued growth of the combined businesses.”
Based in Tampa, Florida, Gardner-Gibson is one of the leading providers of liquid-applied roof coatings, roofing products, driveway sealers and specialty paint, and is recognized for its industry-leading brands. With manufacturing and distribution facilities across the U.S. and Canada, Gardner-Gibson’s products are sold in leading retailers and building supply distributors under the Gardner®, Black Jack®, APOC® and Dyco® brands.
The integration of Gardner-Gibson into ICP’s Building Solutions Group unites premier brands to offer a wide range of products for roofing, building envelope and flooring applications primarily serving commercial facilities and repair and maintenance applications.
“ICP Group has the infrastructure, networks and experience to take Gardner-Gibson to new levels of success,” said Sean Hyer, CEO, Gardner-Gibson. “We’re looking forward to working together and delivering more value to our customers, retail partners and distributors for years to come. It’s an exciting time to be at Gardner-Gibson as we enter this new era of innovation and product expansion with ICP.”
Lazard Middle Market served as financial advisor and Foley & Lardner LLP served as legal counsel to Gardner-Gibson on the transaction. Kirkland & Ellis LLP served as legal counsel to ICP Group on the transaction, and J.P. Morgan, BMO, Antares Capital and Goldman Sachs provided the financing.
For more information about ICP, visit www.icpgroup.com .
The ICP Group is a portfolio company of Audax Private Equity.
About ICP
Innovative Chemical Products (“ICP Group”) is a leading manufacturer of specialty coatings, adhesives and sealants. With operations headquartered in Andover, Massachusetts, and multiple manufacturing facilities around the world, ICP serves multiple end markets, including building envelope, packaging and specialty print. ICP Group is privately held and manufactures products under several recognized specialty groups. For more information, visit www.icpgroup.com .
About ICP Building Solutions Group
ICP Building Solutions Group is the foremost supplier of professional coatings, adhesives and sealants for building envelope and flooring needs. Comprising dozens of industry-leading brands across numerous industries and applications, ICP Building Solutions Group offers the industry’s most comprehensive portfolios to building professionals all over the globe. For more information, visit www.icpgroup.com .
About Gardner-Gibson
Gardner-Gibson, Inc., serves professional contractors and DIYers as a full-line manufacturer of roof, driveway and waterproofing coatings, caulks and sealants. Headquartered in Tampa, Florida, Gardner-Gibson operates manufacturing and distribution facilities across North America. For more information about Gardner-Gibson products, as well as project resources and application tips, visit www.gardner-gibson.com/ .
About Audax Private Equity
Audax Group is a leading alternative investment manager with offices in Boston, New York and San Francisco. Since its founding in 1999, the firm has raised over $27 billion in capital across its Private Equity and Private Debt businesses. Audax Private Equity has invested over $6 billion in more than 135 platforms and over 900 add-on companies, and is currently investing out of its $3.5 billion, sixth private equity fund. Through its disciplined Buy & Build approach, Audax seeks to help platform companies execute add-on acquisitions that fuel revenue growth, optimize operations and significantly increase equity value. With more than 250 employees and over 100 investment professionals, the firm is a leading capital partner for North American middle-market companies. For more information, visit the Audax Group website, www.audaxgroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005795/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom